Herbert Virgin - Feb 22, 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP, Research & CSO
Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2022
Transactions value $
-$39,146
Form type
4
Date filed
2/24/2022, 08:30 PM
Previous filing
Feb 22, 2022
Next filing
Mar 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +70K +66.41% $0.00 175K Feb 22, 2022 Direct F1
transaction VIR Common Stock Options Exercise $2.1K +1.38K +0.78% $1.53* 177K Feb 22, 2022 Direct
transaction VIR Common Stock Sale -$41.3K -1.38K -0.78% $30.00 175K Feb 22, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -1.38K -0.62% $0.00 220K Feb 22, 2022 Common Stock 1.38K $1.53 Direct F3
transaction VIR Stock Option (Right to Buy) Award $0 +70K $0.00 70K Feb 22, 2022 Common Stock 70K $29.48 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
F3 The option is fully vested and exercisable.
F4 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.